ALKS
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Alkermes plc
- Nom
- Alkermes plc
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $7.3B
- Employés
- 2,050
- PDG
- Blair Jackson
- Site web
- http://www.alkermes.com
- Marché
- ACADAXSMJAZZNBIXSUPNVNDA
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 44 472 titres (~2 239 076,26 $ US)
- Insiders
- snyderman nancy lynn MD
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,412,059
Avg sell (VWAP, 90d window) $49.28 vs last close $44.44 (-9.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,172,982 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-03
- Liquidity
- Liquid $94,594,902/day · 20d vol
- Last synced
-
2026-10-27 02:49:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Gaffin David Joseph | Sell · S · 10b5-1 | 2,034 | $41.03 | $83,455 | Form 4 |
| 2026-09-03 | Gaffin David Joseph | Sell · S · 10b5-1 | 2,034 | $48.01 | $97,652 | Form 4 |
| 2026-09-01 | Hopkinson Craig C. | Sell · S · 10b5-1 | 9,000 | $46.99 | $422,874 | Form 4 |
| 2026-08-17 | Nichols Christian Todd | Sell · S · 10b5-1 | 664 | $49.65 | $32,969 | Form 4 |
| 2026-08-03 | Gaffin David Joseph | Sell · S · 10b5-1 | 2,034 | $48.58 | $98,812 | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Sell · S · 10b5-1 | 9,000 | $48.58 | $437,220 | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Sell · S | 44,472 | $50.35 | $2,239,076 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-30 | Gilbert Cisneros | Buy | $15,001 - $50,000 | Filing |
| 2026-07-29 | Gilbert Cisneros | Buy | $15,001 - $50,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-07-30 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ALKS presents a solid financial foundation with strong liquidity (score 90) and healthy fundamentals (score 75), providing a meaningful cushion against near-term headwinds.
The first sentence of the analysis written for ALKS on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. 2 purchase disclosures year to date, a thin reading
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 3.55 · operating margin 17%
Suggested stop 43.65, nearest stored support minus 0.5 ATR(1.8% under the last close). Reward/risk to the next stored resistance is 9.14. Research, not advice. Not an order.
Recent news
- 2026-10-26 Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V. Robeco Institutional Asset Management B.V. trimmed its position in Alkermes plc (NASDAQ: ALKS) by 37.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 57,791 shares of the company''s stock after selling 34,801 shares during the quarter. Robeco
- 2026-10-20 Alkermes to Report Third Quarter Financial Results on November 3, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company''s third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes'' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webca.
- 2026-10-20 Alkermes to Report Third Quarter Financial Results on November 3, 2026 [url="]Alkermes plc[/url] (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to di
- 2026-10-20 Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline Alkermes (ALKS) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-10-20 Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue State of Alaska Department of Revenue lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 43.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,984 shares of the company''s stock after selling 27,857 shares during the period. State of Alaska Department
- 2026-10-13 Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society''s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes'' sleep portfolio following the acquisition.
- 2026-10-09 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
- 2026-10-07 Stock Picks From Seeking Alpha''s September 2026 New Analysts Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
- 2026-10-06 Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE) Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Earnings and Valuation This table compares Alkermes and uniQure"s gross
- 2026-09-30 LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? LQDA''s Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | |
| Ebit Margin | 20.6% | 29.9% | 26.7% | -1.6% | 8.4% | |
| Ebitda Margin | 22.4% | 31.8% | 31.2% | 5.4% | 15.1% | |
| Operating Profit Margin | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | |
| Pretax Profit Margin | 19.7% | 28.5% | 25.3% | -2.8% | 7.5% | |
| Continuous Operations Profit Margin | 16.4% | 23.9% | 31.2% | -3.0% | 6.5% | |
| Net Profit Margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | |
| Bottom Line Profit Margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | |
| Current Ratio | 3.550 | 3.042 | 2.856 | 2.271 | 2.254 | |
| Quick Ratio | 3.188 | 2.649 | 2.497 | 1.906 | 1.935 | |
| Solvency Ratio | 0.378 | 0.670 | 0.461 | -0.087 | 0.033 | |
| Cash Ratio | 2.061 | 0.626 | 0.879 | 0.588 | 0.716 | |
| Price To Earnings Ratio | 19.034 | 12.955 | 12.963 | -26.938 | -77.533 | |
| Price To Earnings Growth Ratio | -0.563 | 3.465 | -0.040 | -0.121 | 1.357 | |
| Forward Price To Earnings Growth Ratio | -0.563 | 3.465 | -0.040 | -0.121 | 1.357 | |
| Price To Earnings Diluted Ratio | 19.566 | 13.253 | 13.210 | -26.938 | -77.533 | |
| Price To Earnings Diluted Growth Ratio | -0.574 | 3.976 | -0.042 | -0.121 | 1.357 | |
| Price To Book Ratio | 2.533 | 3.247 | 3.834 | 4.099 | 3.365 | |
| Price To Sales Ratio | 3.122 | 3.054 | 2.772 | 3.848 | 3.189 | |
| Price To Free Cash Flow Ratio | 9.594 | 11.726 | 13.051 | -248.596 | 51.496 | |
| Price To Operating Cash Flow Ratio | 8.849 | 10.832 | 11.489 | 203.316 | 36.804 | |
| Debt To Assets Ratio | 0.028 | 0.037 | 0.174 | 0.193 | 0.206 | |
| Debt To Equity Ratio | 0.038 | 0.052 | 0.309 | 0.364 | 0.374 | |
| Debt To Capital Ratio | 0.037 | 0.049 | 0.236 | 0.267 | 0.272 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.193 | 0.218 | 0.208 | |
| Financial Leverage Ratio | 1.391 | 1.403 | 1.776 | 1.882 | 1.820 | |
| Working Capital Turnover Ratio | 1.264 | 1.626 | 2.082 | 1.817 | 1.858 | |
| Operating Cash Flow Ratio | 0.958 | 0.944 | 0.772 | 0.042 | 0.216 | |
| Operating Cash Flow Sales Ratio | 0.353 | 0.282 | 0.241 | 0.019 | 0.087 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.922 | 0.924 | 0.880 | -0.818 | 0.715 | |
| Debt Service Coverage Ratio | 14.777 | 18.746 | 23.706 | 3.600 | 11.694 | |
| Interest Coverage Ratio | 20.686 | 18.630 | 17.980 | -0.467 | 8.713 | |
| Short Term Operating Cash Flow Coverage Ratio | 77.194 | 0.000 | 133.784 | 7.015 | 33.905 | |
| Operating Cash Flow Coverage Ratio | 7.439 | 5.813 | 1.078 | 0.055 | 0.244 | |
| Capital Expenditure Coverage Ratio | 12.884 | 13.114 | 8.353 | 0.550 | 3.505 | |
| Dividend Paid And Capex Coverage Ratio | 12.884 | 13.114 | 8.353 | 0.550 | 3.505 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 10.755 | 9.176 | 8.712 | 73.034 | 21.521 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 86.7% | ▲2.4% | ▲2.8% |
| Ebit Margin | 20.6% | ▼-9.4% | ▲3.8% |
| Ebitda Margin | 22.4% | ▼-9.3% | ▲1.2% |
| Operating Profit Margin | 17.2% | ▼-9.8% | ▲1.8% |
| Pretax Profit Margin | 19.8% | ▼-8.7% | ▲4.1% |
| Continuous Operations Profit Margin | 16.4% | ▼-7.5% | ▲1.4% |
| Net Profit Margin | 16.4% | ▼-7.2% | ▲7.8% |
| Bottom Line Profit Margin | 16.4% | ▼-7.2% | ▲7.8% |
| Current Ratio | 3.550 | ▲0.507 | ▲0.755 |
| Quick Ratio | 3.188 | ▲0.539 | ▲0.753 |
| Solvency Ratio | 0.378 | ▼-0.292 | ▲0.087 |
| Cash Ratio | 2.061 | ▲1.435 | ▲1.087 |
| Price To Earnings Ratio | 19.034 | ▲6.079 | ▲30.938 |
| Price To Earnings Growth Ratio | -0.563 | ▼-4.029 | ▼-1.383 |
| Forward Price To Earnings Growth Ratio | -0.563 | ▼-4.029 | ▼-1.383 |
| Price To Earnings Diluted Ratio | 19.566 | ▲6.313 | ▲31.255 |
| Price To Earnings Diluted Growth Ratio | -0.574 | ▼-4.550 | ▼-1.493 |
| Price To Book Ratio | 2.533 | ▼-0.714 | ▼-0.882 |
| Price To Sales Ratio | 3.122 | ▲0.069 | ▼-0.075 |
| Price To Free Cash Flow Ratio | 9.594 | ▼-2.132 | ▲42.140 |
| Price To Operating Cash Flow Ratio | 8.850 | ▼-1.983 | ▼-45.409 |
| Debt To Assets Ratio | 0.028 | ▼-0.009 | ▼-0.100 |
| Debt To Equity Ratio | 0.038 | ▼-0.013 | ▼-0.189 |
| Debt To Capital Ratio | 0.037 | ▼-0.012 | ▼-0.135 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.124 |
| Financial Leverage Ratio | 1.391 | ▼-0.012 | ▼-0.264 |
| Working Capital Turnover Ratio | 1.264 | ▼-0.363 | ▼-0.466 |
| Operating Cash Flow Ratio | 0.958 | ▲0.014 | ▲0.372 |
| Operating Cash Flow Sales Ratio | 0.353 | ▲0.071 | ▲0.157 |
| Free Cash Flow Operating Cash Flow Ratio | 0.922 | ▼-0.001 | ▲0.398 |
| Debt Service Coverage Ratio | 14.777 | ▼-3.969 | ▲0.273 |
| Interest Coverage Ratio | 20.686 | ▲2.055 | ▲7.577 |
| Short Term Operating Cash Flow Coverage Ratio | 77.195 | ▲77.195 | ▲26.815 |
| Operating Cash Flow Coverage Ratio | 7.439 | ▲1.626 | ▲4.513 |
| Capital Expenditure Coverage Ratio | 12.884 | ▼-0.231 | ▲5.202 |
| Dividend Paid And Capex Coverage Ratio | 12.884 | ▼-0.231 | ▲5.202 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 10.755 | ▲1.578 | ▼-13.885 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.61B | $4.76B | $4.61B | $4.28B | $3.74B | |
| Enterprise value | $3.56B | $4.54B | $4.53B | $4.37B | $3.82B | |
| EV / Sales | 2.41x | 2.92x | 2.72x | 3.93x | 3.26x | |
| EV / Op. cash flow | 6.83x | 10.34x | 11.28x | 207.45x | 37.58x | |
| EV / Free cash flow | 7.41x | 11.20x | 12.81x | -253.65x | 52.58x | |
| EV / EBITDA | 10.76x | 9.18x | 8.71x | 73.03x | 21.52x | |
| Net debt / EBITDA | -3.17x | -0.44x | -0.16x | 1.46x | 0.44x | |
| Current ratio | 3.55x | 3.04x | 2.86x | 2.27x | 2.25x | |
| Income quality | 2.15x | 1.20x | 1.13x | -0.13x | -2.11x | |
| Graham number | $19 | $21 | $19 | — | — | |
| Graham net-net | $6 | $3 | $1 | $0 | -$0 | |
| Tax burden | 82.9% | 82.7% | 84.4% | 508.4% | -54.9% | |
| Interest burden | 96.0% | 95.2% | 94.8% | 172.1% | 88.7% | |
| Working capital | $1.39B | $950.2M | $965.3M | $632.6M | $590.9M | |
| Invested capital | $1.77B | $1.35B | $1.37B | $1.07B | $1.21B | |
| Return on assets | 9.6% | 17.9% | 16.7% | -8.1% | -2.4% | |
| Operating ROA | 11.1% | 20.1% | 20.2% | -0.3% | 4.9% | |
| Return on tangible assets | 9.9% | 18.6% | 17.3% | -8.6% | -2.6% | |
| Return on equity | 13.3% | 25.1% | 29.6% | -15.2% | -4.3% | |
| Return on invested capital | 10.6% | 22.1% | 25.5% | -0.4% | 5.4% | |
| Return on capital employed | 12.8% | 26.4% | 25.6% | -0.4% | 6.3% | |
| Earnings yield | 5.2% | 7.7% | 7.7% | -3.7% | -1.3% | |
| Free cash flow yield | 10.4% | 8.5% | 7.7% | -0.4% | 1.9% | |
| Capex / Op. cash flow | 7.8% | 7.6% | 12.0% | 181.8% | 28.5% | |
| Capex / Depreciation | 148.8% | 117.4% | 64.1% | 49.1% | 36.9% | |
| Capex / Sales | 2.7% | 2.1% | 2.9% | 3.4% | 2.5% | |
| SG&A / Sales | 48.4% | 41.4% | 41.5% | 53.1% | 46.8% | |
| R&D / Sales | 22.0% | 15.7% | 16.3% | 24.5% | 24.8% | |
| Stock comp / Sales | 6.7% | 6.2% | 6.1% | 8.5% | 7.5% | |
| Intangibles / Total assets | 3.3% | 4.1% | 4.0% | 6.1% | 8.2% | |
| Days sales outstanding | 83d | 91d | 73d | 97d | 102d | |
| Days payables outstanding | 201d | 68d | 95d | 55d | 103d | |
| Operating cycle | 448d | 363d | 342d | 401d | 380d | |
| Cash conversion cycle | 247d | 295d | 247d | 346d | 277d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years